Treatment in Diabetes (Pharmacy Dept)

8/16/2019 Treatment in Diabetes (Pharmacy Dept)

1/4

Viglip® is indicated

in the treatment

of type 2 diabetes.

C Pharmaceutical Ltd. Presents Viglip®Vildagliptin 50 mg tablet


2/4

Comparison with metformin

Vildagliptin is as superior as Metformin. In a

noninferiority trial, 780 patients !b"#c 7.5$%##.0$,

a&erage 8.7$' (ere randomi)ed to &ildagliptin 50 mg

bid n * 52+' or metformin #000 mg bid n * 25' for

52 (ee-s. Mean changes in !b"#c (ere #.0$ (ith

&ildagliptin p / 0.00#' and #.$ (ith metformin

p / 0.00#' i1unyer 34..et al., 2007'

Efcacy prole o Vildagliptin

Vildagliptin is a ne( anti1diabetic agentthat enhances pancreatic islet cell responsi&eness

to glucose. "n etensi&e clinical program in&ol&ing

approimately 22,000 patients and 7000 patient1years

of eposure to &ildagliptin has sho(n that the agent is

(ell tolerated and efficacious in impro&ing glycemic

control in patients (ith type 2 diabetes mellitus 62M'.

Monotherapy trials ha&e sho(n that 80$ !b"#c

lo(ering is accompanied by body (eight1neutral

and lipid1neutral effects, lo( ris- of edema, and

lo( ris- of hypoglycemia Mathieu .et al., 2008' .


3/4

Comparison with rosiglitazone

Vildagliptin is more superior than9osiglita)one. In a noninferiority trail,

78+ patients !b"#c 7.5$1##.0$, mean 8.7$'

(ere randomi)ed to &ildagliptin 50 mg bid

n * 5#:' or rosiglita)one 8 mg ;d n * 2+7'

for 2 (ee-s. Mean changes in !b"#c from

baseline (ere #.


4/4

6he abo&e mention studies pro&ed that Vildagliptin is1

!ighly effecti&e

Aell absorbed orally

!igher safety profile

"hrBn C, ch(ei)er ", e>ager , Villhauer DC, unning CD, 3oley ED.

FMechanisms =f "ction =f 6he ipeptidyl eptidase1 Inhibitor Vildagliptin

In !umans. 1 ubmed 1 ?CIF.G=nlineH "&ailable at Ncbi.nlm.nih.gov.

G"ccessed#5 May 20#+H.

hantal Mathieu, D&y egrande. FVildagliptin " ?e( =ral 6reatment 3or

6ype 2 iabetes MellitusF. Vascular Health and Risk Management .+ 2008'

#

Treatment in Diabetes (Pharmacy Dept)

Documents